Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology with human disease to advance novel therapeutics that target and improve the integrity of the intestinal barrier.

Company profile
Ticker
PALI
Exchange
Website
CEO
Kenneth Carter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...
Former names
Neuralstem, Inc., Seneca Biopharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
Leading Biosciences, Inc. • Suzhou Neuralstem Biopharmaceutical Co., Ltd. ...
IRS number
522007292
PALI stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
14 Sep 23
8-K
Entry into a Material Definitive Agreement
11 Sep 23
8-K
Entry into a Material Definitive Agreement
11 Sep 23
424B5
Prospectus supplement for primary offering
11 Sep 23
8-K
Entry into a Material Definitive Agreement
8 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Entry into a Material Definitive Agreement
9 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
EFFECT
Notice of effectiveness
28 Apr 23
424B3
Prospectus supplement
27 Apr 23
Latest ownership filings
4
Robert J. Trenschel
15 Sep 23
SC 13G
L1 Capital Global Opportunities Master Fund, Ltd.
15 Sep 23
SC 13G
Lind Global Fund II LP
15 Sep 23
4
John David Finley
14 Sep 23
3
Mitchell Lawrence Jones
13 Sep 23
4
John David Finley
13 Sep 23
4
John David Finley
14 Aug 23
4
John David Finley
6 Jul 23
4
John David Finley
14 Jun 23
4
Robert J. Trenschel
13 Jun 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.43 mm | 16.43 mm | 16.43 mm | 16.43 mm | 16.43 mm | 16.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.20 mm | 1.20 mm | 733.00 k | 1.01 mm |
Cash used (since last report) | n/a | n/a | 3.39 mm | 3.38 mm | 2.07 mm | 2.84 mm |
Cash remaining | n/a | n/a | 13.04 mm | 13.04 mm | 14.36 mm | 13.59 mm |
Runway (months of cash) | n/a | n/a | 10.8 | 10.9 | 19.6 | 13.5 |
Institutional ownership, Q2 2023
37.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 231.70 mm |
Total shares | 2.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Regional Medical Center Yuma | 2.25 mm | $5.55 mm |
Intracoastal Capital | 131.09 k | $0.00 |
Geode Capital Management | 42.25 k | $71.82 mm |
Vanguard | 35.57 k | $60.47 mm |
Lind Global Fund II | 30.99 k | $0.00 |
BAC Bank Of America | 30.00 k | $51.00 mm |
STT State Street | 22.46 k | $38.19 mm |
MS Morgan Stanley | 2.04 k | $3.47 mm |
WFC Wells Fargo & Co. | 372.00 | $633.00 k |
Advisor | 221.00 | $376.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Sep 23 | Robert J. Trenschel | Common Stock, par value $0.01 | Sell | Dispose S | No | No | 0.64 | 300 | 192.00 | 0 |
13 Sep 23 | John David Finley | Common Stock, par value $0.01 | Buy | Acquire P | No | No | 0.655 | 15,000 | 9.83 k | 28,394 |
12 Sep 23 | John David Finley | Common Stock, par value $0.01 | Payment of exercise | Dispose F | No | No | 0.655 | 1,792 | 1.17 k | 13,394 |
11 Sep 23 | John David Finley | Common Stock, par value $0.01 | Option exercise | Acquire M | No | No | 0 | 5,558 | 0.00 | 15,186 |
11 Sep 23 | John David Finley | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,558 | 0.00 | 61,142 |
11 Aug 23 | John David Finley | Common Stock, par value $0.01 | Payment of exercise | Dispose F | No | No | 0.7 | 1,040 | 728.00 | 9,628 |
6 Aug 23 | John David Finley | Common Stock, par value $0.01 | Option exercise | Acquire M | No | No | 0 | 3,475 | 0.00 | 11,057 |
6 Aug 23 | John David Finley | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,475 | 0.00 | 34,750 |
News
Press releases
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
11 Sep 23
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
11 Sep 23
Thinking about buying stock in Palisade Bio, Faraday Future Intelligent Electric, BioNexus Gene Lab, Taysha Gene Therapies, or Actelis Networks?
8 Sep 23
Thinking about buying stock in Tilray Brands, GameStop, Mullen Automotive, Palisade Bio, or Wheeler Real Estate Investment Trust?
7 Sep 23
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
7 Sep 23